Vijaypd Ceutical IPO is a fixed price issue of ₹19.25 crores. The issue is entirely a fresh issue of 0.55 crore shares of ₹19.25 crore.
The IPO opens for subscription on September 29, 2025, to October 1, 2025.
The basis of allotment is expected to be finalised on October 3, 2025. The shares are proposed to be listed on the NSE SME, with a tentative listing date of October 7, 2025. The issue price for Vijaypd Ceutical IPO has been fixed at ₹35 per share.
The lot size is set at 4000 shares. A retail investor is required to make a minimum investment of ₹2,80,000 for 8000 shares. For High Net-worth Individuals (HNIs), the minimum application is for 3 lots or 12,000 shares, amounting to ₹4,20,000.
Smart Horizon Capital Advisors Pvt Ltd is the book running lead manager and Kfin Technologies Ltd is the registrar of the issue. The market maker of the company is Shreni Shares Ltd. Refer to Vijaypd Ceutical IPO RHP for complete details.
Vijaypd Ceutical IPO Objectives
The company plans to allocate the net proceeds from the issuance to the following purposes:
- Upto ₹1,082.83 lakh will be earmarked for funding capital expenditure requirements of the company towards the construction of Pharmaceutical API/Intermediates and Chemicals manufacturing plant and purchase of new machineries in MIDC – Shrirampur, Ahmednagar, Maharashtra.
- Upto ₹510.00 lakh will be allocated for repayment/prepayment of all or certain borrowings availed by the company.
- Upto ₹74.17 lakh will be utilised for general corporate purposes.
About Vijaypd Ceutical Limited
Vijaypd Ceutical Limited is engaged in the business of distribution and supply within the pharmaceutical and consumer goods sectors, offering a comprehensive range of services. The company operates as a representative, dealer, agent, stockist, supplier, trader, and packer. Its product portfolio serves both the pharmaceutical and wellness industries, as well as the fast-moving consumer goods (FMCG) market.
The company’s pharmaceutical and wellness products include medicines such as injections, tablets, capsules, ointments, suppositories, ophthalmic preparations, and liquid oral formulations. Additionally, Vijaypd Ceutical supplies vitamins, hormones, enzymes, wellness tonics, serums, and diagnostic test kits. In the FMCG segment, the company provides personal care and toiletry products, including soaps, sanitizers, and baby care items, along with ayurvedic products, cosmetics, food products, dental products, and crude drugs.
A pharmaceutical supply chain involves multiple stages, from manufacturing to distribution and the delivery of medicines and vaccines to end consumers. This process includes drug distribution, inventory management, pharmaceutical logistics, and overall supply chain management, with participation from manufacturers, suppliers, distributors, logistics partners, shippers, and pharmaceutical retailers.
As a distributor of pharmaceutical products, Vijaypd Ceutical Limited leverages advanced technology to deliver comprehensive healthcare solutions to pharmacies, nursing homes, and clinics across Western Suburban Mumbai, South Mumbai, Ratnagiri, Aurangabad, and Akola. The company operates three distribution warehouses in Mumbai, ensuring timely and efficient deliveries.
As of March 31, 2025, Vijaypd Ceutical’s customer base comprises over 2,109 pharmacies, clinics, and nursing homes across four districts, covering 20 locations. Its distribution network is supported by relationships with more than 170 healthcare product manufacturers, providing access to a diverse range of over 19,000 stock-keeping units (SKUs). This extensive portfolio enables the company to meet the evolving needs of its customers while maintaining high standards of quality and reliability in pharmaceutical supply.
Industry Outlook
- India’s dominance in the global generic formulation space is expected to continue, supported by timely launches of generic drugs in markets like the US and increasing acceptance of generics in developed countries.
- Exports remain a key growth engine, particularly to the US market, while domestic demand is bolstered by an aging population and rising incidence of lifestyle diseases, supporting revenue growth.
- After a temporary slowdown due to the COVID-19 pandemic, the Indian pharmaceutical industry is expected to achieve a CAGR of 10% from FY 2024-30, with the annual revenue turnover projected to reach INR 7,300 billion by FY 2030.
How To Apply for the Vijaypd Ceutical IPO Online?
- Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
- Locate the IPO Section: Navigate to the 'IPO' section on the platform.
- Select IPO: Find and select the Vijaypd Ceutical IPO from the list of open IPOs.
- Enter the Lot Size: Specify the number of lots you want to bid for.
- Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
- Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.
How To Check the Allotment Status of Vijaypd Ceutical IPO?
Steps to check IPO allotment status on Angel One’s app:
- Log in to the Angel One app.
- Go to the IPO Section and then to IPO Orders.
- Select the individual IPO that you had applied for and check the allotment status.
- Angel One will notify you of your IPO allotment status via push notification and email.
Contact Details of Vijaypd Ceutical Limited
Registered office: A/1, 1st Floor, Devraj Premises CHSL, Goregaon West, Mumbai, Maharashtra, 400062
Phone: +91 9820917040
Email: investors@vijaypdceutical.com
Vijaypd Ceutical IPO Reservation
|
Investor Category |
Shares Offered |
|
Market Maker Shares Offered |
2,84,000 (5.16%) |
|
NII (HNI) Shares Offered |
26,08,000 (47.42%) |
|
Retail Shares Offered |
26,08,000 (47.42%) |
|
Total Shares Offered |
55,00,000 (100.00%) |
Vijaypd Ceutical IPO Lot Size Details
|
Application |
Lots |
Shares |
Amount |
|
Individual investors (Retail) (Min) |
2 |
8,000 |
₹2,80,000 |
|
Individual investors (Retail) (Max) |
2 |
8,000 |
₹2,80,000 |
|
HNI (Min) |
3 |
12,000 |
₹4,20,000 |
Vijaypd Ceutical IPO Promoter Holding
Samit Madhukar Shah, Bhavin Dhirendra Shah, Rahul Dhirendra Shah, Narendra Nagindas Shah, Dina Madhukar Shah and Hemanti Jitendra Shah are the promoters of the company
|
Share Holding Pre-Issue |
78.30% |
|
Share Holding Post Issue  |
56.25% |
Note: Equity dilution will be determined by subtracting the Shareholding Post Issue from the Shareholding Pre Issue.
Key Performance Indicators for Vijaypd Ceutical IPO
|
KPI |
Value |
|
RoCE (%) |
17.30 |
|
Debt/Equity  |
0.68 |
|
RoNW (%) |
14.91 |
|
PAT Margin (%) |
4.49 |
|
EBITDA Margin (%) |
8.04 |
Vijaypd Ceutical IPO Prospectus
Vijaypd Ceutical IPO Registrar and Lead Managers
Vijaypd Ceutical IPO Lead Managers
- Smart Horizon Capital Advisors Pvt Ltd
Registrar for Vijaypd Ceutical IPO
Kfin Technologies Ltd
- Phone: 04067162222, 04079611000
- Email: ipo@kfintech.com
- Website: https://ipostatus.kfintech.com/
Financial Performance of Vijaypd Ceutical Limited
| Particulars | As of March 31, 2025 | As of March 31, 2024 |
|---|---|---|
| Revenue from Operations (₹ lakh) | 10,681.01 | 5,432.81 |
| EBITDA (₹ lakh) | 859.12 | 486.99 |
| Net Profit / Loss After Tax (₹ lakh) | 479.55 | 165.02 |
| Current Ratio (times) | 1.90 | 0.95 |
Know before investing
Strengths
8Strategic location in Western Mumbai Suburban enables quick distribution and strong client relationships with pharmacies, clinics, and nursing homes.
Diverse product portfolio covering pharmaceuticals, wellness, OTC, baby care, and specialty medicines caters to broad healthcare needs.
Experienced management and promoters with over six decades of industry knowledge drive business growth and execution.
Streamlined supply chain ensures reduced lead times, lower inventory costs, and timely delivery, enhancing competitive advantage.
Plans to enter manufacturing of APIs and excipients offer revenue diversification and vertical integration opportunities.
Inorganic expansion through acquisitions helps increase geographic reach, market share, and wallet share from customers.
Focus on operating efficiency with warehouse automation and scale benefits supports profitability and cost optimisation.
Marketing and distribution collaborations with healthcare product manufacturers provide integrated solutions to expand brand reach in India.
Risks
8Expansion into API manufacturing may expose the company to operational, financial, and regulatory risks affecting growth and cash flows.
Distribution of expired, defective, or counterfeit products could lead to losses, reputational damage, and product liability claims.
Heavy reliance on customers and suppliers in Maharashtra makes the company vulnerable to regional disruptions.
Dependence on pharmaceutical industry demand exposes the business to sector downturns or sales fluctuations.
Inorganic growth through acquisitions carries risks of integration challenges and failure to realize expected benefits.
High dependence on imported raw materials, particularly from China, poses supply chain and production risks.
Strict quality regulations from agencies like US FDA require compliance; any lapses can result in penalties or export suspension.
Intense competition from domestic and imported APIs and fragmented distribution networks may impact market share and margins.
Vijaypd Ceutical Limited Peer Comparison
| Company | EPS (Basic) | Basic EPS (₹) | P/E Ratio | Return on Net Worth (%) |
|---|---|---|---|---|
| Vijaypd Ceutical Limited | - | 3.84 | 9.11 | 14.91 |
| MedPlus Health Services Limited | - | 3.37 | 249.42 | 3.32 |
| Entero Healthcare Solutions Limited | - | 4.41 | 256.17 | 1.17 |
